Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?

被引:8
|
作者
Hasbek, Zekiye [1 ]
Turgut, Bulent [1 ]
机构
[1] Cumhuriyet Univ, Fac Med, Dept Nucl Med, Sivas, Turkey
关键词
Thyroid cancer; thyroid stimulating hormone level; radioiodine therapy;
D O I
10.4274/mirt.88598
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: Remnant ablation with radioactive iodine (I-131) is a successful form of treatment that aims to destroy the remaining residual tissue and/or metastatic tissue after total thyroidectomy in differentiated thyroid cancer (DTC) patients. High level of thyroid stimulating hormone (TSH) (>= 30 mIU/L) is recommended for success of ablation treatment. In this retrospective study, our aim was to investigate whether the TSH levels at the time of ablation effect the success of radioactive iodine remnant ablation. Methods: Patients who were diagnosed with DTC, treated with bilateral total/near total thyroidectomy and who were referred for I-131 remnant ablation were included in this study. Patients with undetectable TSH-stimulated serum thyroglobulin (Tg) level, normal physical examination, negative results on whole body scan with I-131, and no evidence of neck lymph node metastasis on ultrasound were defined as disease-free. The correlation between TSH level at the time of ablation and ablation success was assessed. Results: Two hundred sixty one consecutive patients were included in the present study. Mean TSH level was 19.47 +/- 6 mIU/L in the 34 patients with TSH <30 mIU/L, while mean TSH level was 73.65 +/- 27 mIU/L in the 227 patients with TSH >= 30 mIU/L during I-131 remnant ablation. Ablation was unsuccessful in only one patient with TSH <30 mIU/L who had lung metastasis. Ablation was unsuccessful in 5.1% of patients with TSH >= 30 mIU/L. The effect of TSH level was not significant on ablation success (p=0.472). Conclusion: In conclusion, we think that a high TSH serum level alone is not a factor for the success of ablation. Age, presence of metastasis, extent of residual thyroid mass should also be considered. Especially, in the presence of metastatic tissue, obtaining adequate increase in TSH level is not always possible. The success of ablation at lower levels of TSH elevations may be sufficient for patients, and long-term hypothyroidism may not be required.
引用
收藏
页码:79 / 84
页数:6
相关论文
共 50 条
  • [1] Is too high TSH level necessary in differentiated thyroid cancer for success in ablation?
    Hasbek, Z.
    Turgut, B.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S537 - S537
  • [2] Recombinant thyroid-stimulating hormone in differentiated thyroid cancer
    Krausz, Y
    Uziely, B
    Nesher, R
    Chisin, R
    Glaser, B
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2001, 3 (11): : 843 - +
  • [3] Correlation analyses of thyroid-stimulating hormone and thyroid autoantibodies with differentiated thyroid cancer
    Zhang, Xuefeng
    Zhang, Xueqi
    Change, Zhexing
    Wu, Cuicui
    Guo, Hang
    [J]. JOURNAL OF BUON, 2018, 23 (05): : 1467 - 1471
  • [4] Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
    Berg, G
    Lindstedt, G
    Suurküla, M
    Jansson, S
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (01) : 44 - 52
  • [5] Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
    G. Berg
    G. Lindstedt
    M. Suurküla
    S. Jansson
    [J]. Journal of Endocrinological Investigation, 2002, 25 : 44 - 52
  • [6] The role of higher pre-ablation serum thyroid stimulating hormone level in predicting effectiveness of radioiodine ablation of differentiated thyroid carcinoma.
    Lawal, Ismaheel
    Nyakale, Nozipho
    Lengana, Thabo
    Harry, Lerwine
    Mokgoro, Neo
    Vorster, Mariza
    Sathekge, Machaba
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [7] The role of higher pre-ablation serum thyroid stimulating hormone level in predicting effectiveness of radioiodine ablation of differentiated thyroid carcinoma.
    Lawal, Ismaheel
    Nyakale, Nozipho
    Harry, Lerwine
    Lengana, Thabo
    Mokgoro, Neo
    Vorster, Mariza
    Sathekge, Machaba
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [8] Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma
    Lawal, Ismaheel O.
    Nyakale, Nozipho E.
    Harry, Lerwine M.
    Lengana, Thabo
    Mokgoro, Neo P.
    Vorster, Mariza
    Sathekge, Mike M.
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2017, 38 (03) : 222 - 227
  • [9] Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal preparation for radioiodine ablation in differentiated thyroid cancer in children, adolescents and young adults
    Schumm, Max A.
    Pyo, Howard Q.
    Kim, Jiyoon
    Tseng, Chi-Hong
    Yeh, Michael W.
    Leung, Angela M.
    Chiu, Harvey K.
    [J]. CLINICAL ENDOCRINOLOGY, 2021, 95 (02) : 344 - 353
  • [10] Thyroid-stimulating hormone receptor (TSHR) as a target for imaging differentiated thyroid cancer
    Gimblet, Grayson R.
    Whitt, Jason
    Houson, Hailey A.
    Lin, Diana
    Guenter, Rachael
    Rao, Tejeshwar C.
    Wang, Dezhi
    Ness, John
    Gonzalez, Manuel Lora
    Murphy, Madisen S.
    Gillis, Andrea
    Chen, Herbert
    Copland, John A.
    Kenderian, Saad S.
    Lloyd, Ricardo V.
    Szkudlinski, Mariusz W.
    Lapi, Suzanne E.
    Jaskula-Sztul, Renata
    [J]. SURGERY, 2024, 175 (01) : 199 - 206